Medtronic to invest $50 million over 5 years in New Diabetes Global Capability Centre in Pune
Pune, 16th June 2025: Medtronic plc, a global leader in healthcare technology, has inaugurated a new Global Capability Centre (GCC) in Pune, India for its Diabetes business. Over the next five years, an investment of $50 million will support the establishment and expansion of the new centre. Designed to drive innovation and operational excellence, the centre is expected to create over 300 service and software jobs in the first year of operations, with plans to double this number over the next four years.
For over four decades, the Diabetes business has served people living with diabetes through groundbreaking innovations with the goal of improving outcomes and giving people the freedom to forget about their diabetes. This world-class, state-of-the-art centre in Pune, India will enable the company’s commitment to continue to fulfill this mission.
The Diabetes GCC will be a centre of excellence that enhances customer care, advanced analytics, digital tech services while also supporting patient financial services, and operations. This expansion in India will also unlock a diverse array of job opportunities in these functions.
As GCCs continue to reshape global business landscapes, India has emerged as a pivotal hub for these centres. With industry reports estimating the country’s GCC market to surpass $100 billion by 2030 and create over 2.5 million jobs.[1] Among key locations, Pune has distinguished itself as a preferred destination, offering a skilled talent pool and a thriving technology ecosystem enriched by a dynamic startup culture.[2]
Commenting on the inauguration, Que Dallara, EVP & President, Medtronic Diabetes, said, “In recent years, India has firmly established itself as a leading global IT hub. The incredible depth of talent in Pune and across India aligns with our purpose: to support people living with diabetes with solutions that truly make life
easier. This centre isn’t just about growth — it’s a meaningful step forward in our mission to simplify diabetes care and reach more people around the world.”
Vijendra Singh, Medtronic Diabetes, Global Capability Centre India Site Director & Sr. Customer Service Director adds, “The inauguration of this centre not only enhances our capabilities but reinforces our dedication to transforming diabetes management worldwide through operational excellence. We plan to work in close collaboration with local bodies, to drive meaningful progress in healthcare and create talent opportunities in the region.”
This significant investment reinforces Medtronic’s commitment to strengthening India’s healthcare and technology ecosystem, supporting the growing demand for GCCs, and enhancing operational efficiencies to drive innovation and better patient outcomes.
Medtronic recently announced its intent to separate the Diabetes business into an independent, standalone publicly traded company, which will be called MiniMed once it begins operating as a standalone business.
About the Diabetes Business at Medtronic (www.medtronicdiabetes.com) Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We’ve pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.
